China is an obvious priority country because of its size and because headache prevalence has, historically, been significantly underestimated there (erroneously reducing the estimate of global burden). A nationwide population-based door-to-door has been completed there.

A study is planned in Australia, subject to a grant application to the National Health and Medical Research Council from the University of Canberra.

Collaborators:

• X-T Cao, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China
• Stuart Cathcart, University of Canberra, Canberra, New South Wales, Australia
• Y-N Fang, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China
• J-C Feng, The First Hospital of Jilin University, Changchun, Jilin Province, China
• M-W He, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China,
• R-Z Liu, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China
• X-Y Qiao, Affiliated Huashan Hospital of Fudan University, Shanghai, China
• F Sakai, Kitasato University Hospital, Kitasato, Sagamihara, Kanagawa, Japan
• X-S Yang, Xiangya Hospital of Centre-South University, Changsha, Hunan Province, China
• S-Yu, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China
• G Zhao, The Fourth Military Medical University, Xian, Shaanxi Province, China